Source: Virtual Congress 2021 – Highlights for primary care in 2021



Rating:

Share or cite this content

Citations should be made in the following way:
M. Crooks (East Riding of Yorkshire, United Kingdom), L. Crowther (East Riding of Yorkshire, United Kingdom), H. Cummings (East Riding of Yorkshire, United Kingdom), J. Cohen (East Riding of Yorkshire, United Kingdom), C. Huang (East Riding of Yorkshire, United Kingdom), A. Morice (East Riding of Yorkshire, United Kingdom), S. Faruqi (East Riding of Yorkshire, United Kingdom), J. Birchall (Cheshire, United Kingdom), Y. Xu (Luton, United Kingdom), T. Morris (Luton, United Kingdom). Late Breaking Abstract - Impact of maintenance and reliever therapy (MART)-focused asthma guideline on SABA prescriptions. 80

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Cost effectiveness of as-needed budesonide/formoterol vs low-dose ICS maintenance therapy in mild asthma patients: A UK perspective Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness Year: 2019 Efficacy of budesonide/formoterol maintenance and reliever therapy in mild asthma Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013 The budesonide/formoterol inhaler as maintenance and reliever therapy in Maori asthmatics Source: Annual Congress 2013 –Treatment and management of asthma in primary care Year: 2013 Late Breaking Abstract - Short-term and maintenance oral corticosteroid use for German patients with asthma Source: International Congress 2019 – Powerful cohort studies with/without lung function Year: 2019 Late Breaking Abstract - Open-label trial of budesonide/formoterol reliever therapy in mild asthma Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 Late Breaking Abstract - Overestimation of asthma control and misperception of short-acting ß2-agonists (SABA) use among physicians in Poland Source: Virtual Congress 2020 – Prediction of outcomes in obstructive diseases Year: 2020 Budesonide/formoterol maintenance and reliever therapy in adolescent patients with asthma Source: International Congress 2016 – Novel mechanisms and treatment modalities in asthma Year: 2016 Once-daily tiotropium respimat add-on to at least ICS maintenance therapy reduces exacerbation risk in patients with uncontrolled symptomatic asthma Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Late Breaking Abstract - Overprescription of short-acting beta2-agonists in asthma management? Pharmacy reports from 91,673 patients in Poland Source: International Congress 2019 – New towards old therapies in airway diseases Year: 2019 Late Breaking Abstract - Difference in clinical outcomes between smoking and non-smoking asthma patients who initiated an ICS or ICS/LABA treatment Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Late Breaking Abstract - The burden of intermittent oral corticosteroid use in asthma Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science Year: 2021 Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Predictors of excessive short-acting beta2-agonist use and asthma exacerbations: a retrospective analysis of a Polish prescription database. Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 Episodic high reliever use with budesonide/formoterol maintenance and reliever therapy confers added protection against asthma exacerbations Source: Annual Congress 2007 - Recent advances in our understanding of the treatment of asthma Year: 2007 Budesonide/formoterol maintenance and reliever therapy for asthma in general practice: is it cost-effective? Source: Annual Congress 2008 - Diagnosing, monitoring and treating respiratory diseases in primary care Year: 2008 Late Breaking Abstract - Impact of ICS/LABA and LABA/LAMA FDCs on lung function and exacerbation of COPD: a network meta-analysis Source: International Congress 2018 – Pharmacological management of COPD Year: 2018 ICS-formoterol reliever versus ICS and short-acting ß2-agonist reliever in asthma: a systematic review and meta-analysis Source: ERJ Open Res, 7 (1) 00701-2020; 10.1183/23120541.00701-2020 Year: 2021 Budesonide/formoterol maintenance and reliever therapy use in elderly asthma patients Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Efficacy and safety of indacaterol acetate on ICS background therapy in asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014